Frontiers
US$ 22.92
side effects of glp-1 agonists Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus Clinical Recommendations to Manage Gastrointestinal
Description
AANA News and Resources
Wegovy is the same active ingredient, semaglutide, dosed higher and FDA-approved specifically for chronic weight management
Key takeaway: GLP-1 RAs do not appear to increase pancreatitis risk, and may be associated with improved outcomes if pancreatitis occurs
Additionally, age should be considered as a crucial factor for randomization and balance in the design of clinical trials for weight reduction medications
W.SpectorA
Amato A, et al
